GlassScriptPhysician profile
Juan Liu
NPI 1396100095
$6,025.32
in general payments reported to CMS, 2019-2025
23 companies · $2,438 in 2025
The $2,438 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $472 · 2022: $724 · 2023: $843 · 2024: $1,548 · 2025: $2,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,639 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,639.37 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.62 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $566.29 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $510.18 | 2021-2025 | Blu-U, Odomzo, Winlevi |
| Leo Pharma INC. | $486.38 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $475.92 | 2021-2025 | |
| Janssen Biotech, INC. | $468.43 | 2023-2025 | Tremfya |
| Dermavant Sciences, INC. | $452.76 | 2023-2024 | Vtama |
| Incyte Corporation | $374.83 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $328.75 | 2023-2025 | Nemluvio, Aklief, Epsolay |
| Lilly USA, LLC | $271.66 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $213.98 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $206.27 | 2021-2025 | Dupixent |
| Organon LLC | $175.67 | 2025 | Vtama, Nexplanon |
| Allergan, INC. | $144.42 | 2022 | |
| Ucb, INC. | $137.80 | 2021-2025 | Bimzelx, Cimzia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $130.18 | 2021 | |
| Almirall LLC | $128.05 | 2021-2024 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $127.20 | 2022-2025 | Sotyktu |
| Pfizer INC. | $70.13 | 2025 | |
| Amgen INC. | $59.81 | 2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $55.54 | 2024-2025 | Cabtreo, Jublia |
| Lnhc, INC | $18.92 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $15.53 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.